David-Alexandre C. Gros

David-Alexandre C. Gros is the Chief Executive Officer and co-founder of Imbria Pharmaceuticals Inc., where he also served as Chairman of the Board of Directors. His extensive experience in the pharmaceutical and healthcare industries includes roles such as President and Chief Operating Officer of Neurocrine Biosciences, Inc., and Chief Business and Principal Financial Officer at Alnylam Pharmaceuticals, Inc. Additionally, he worked as Chief Strategy Officer at Sanofi, S.A., and held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc. Gros also has experience in healthcare consulting from his time at McKinsey & Company. He co-founded Eliem Therapeutics, Inc., and served on its Board of Directors, as well as the Board of Directors of Saint Jean Groupe, S.A. He earned a Doctor of Medicine from The Johns Hopkins University School of Medicine, holds a Master of Business Administration from Harvard Business School, and received a Bachelor of Arts from Dartmouth College.